Biomarkers /
EGFR Codon 719 Missense
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
EGFR Codon 719 Missense is a predictive biomarker for use of afatinib, capmatinib, crizotinib, dacomitinib, erlotinib, gefitinib, and cetuximab in patients.
Of the therapies with EGFR Codon 719 Missense as a predictive biomarker, 7 have NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against EGFR Codon 719 Missense or its related pathways [5].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Cetuximab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, may be considered after progression on on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
EGFR Codon 719 Missense serves as an inclusion eligibility criterion in 52 clinical trials, of which 44 are open and 8 are closed. Of the trials that contain EGFR Codon 719 Missense as an inclusion criterion, 12 are phase 1 (9 open), 7 are phase 1/phase 2 (6 open), 27 are phase 2 (25 open), and 6 are phase 3 (4 open).
Trials with EGFR Codon 719 Missense in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, non-squamous non-small cell lung carcinoma, lung adenocarcinoma, malignant solid tumor, and squamous cell lung carcinoma [5].
Pembrolizumab, pemetrexed, carboplatin, durvalumab, and nivolumab are the most frequent therapies in trials with EGFR Codon 719 Missense as an inclusion criteria [5].
Significance of EGFR Codon 719 Missense in Diseases
Non-Small Cell Lung Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 40 clinical trials for non-small cell lung carcinoma, of which 34 are open and 6 are closed. Of the trials that contain EGFR Codon 719 Missense and non-small cell lung carcinoma as inclusion criteria, 10 are phase 1 (8 open), 7 are phase 1/phase 2 (6 open), 19 are phase 2 (17 open), and 4 are phase 3 (3 open) [5].
Afatinib, capmatinib, cetuximab, crizotinib, dacomitinib, erlotinib, and gefitinib have evidence of efficacy in patients with EGFR Codon 719 Missense in non-small cell lung carcinoma [5].
Lung Adenocarcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 7 clinical trials for lung adenocarcinoma, of which 5 are open and 2 are closed. Of the trials that contain EGFR Codon 719 Missense and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 2 (4 open), and 2 are phase 3 (1 open) [5].
Malignant Solid Tumor +
EGFR Codon 719 Missense is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 6 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].
Breast Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [5].
Melanoma +
EGFR Codon 719 Missense is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Bladder Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Colorectal Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and colorectal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Head And Neck Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Urothelial Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR Codon 719 Missense and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bile Duct Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bronchogenic Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Squamous Cell Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Diffuse Midline Glioma, H3 K27M-Mutant +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gallbladder Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Adenocarcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Glioblastoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Hepatocellular Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Lung Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Mesothelioma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Multiple Myeloma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Adenocarcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Pancreatic Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Prostate Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Renal Cell Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Small Cell Lung Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Soft Tissue Sarcoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Squamous Cell Lung Carcinoma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
WHO Grade III Glioma +
EGFR Codon 719 Missense is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR Codon 719 Missense and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
